Harbour Investments Inc. Cuts Holdings in Novo Nordisk A/S (NYSE:NVO)

Harbour Investments Inc. reduced its position in Novo Nordisk A/S (NYSE:NVO) by 5.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,132 shares of the company’s stock after selling 587 shares during the quarter. Harbour Investments Inc.’s holdings in Novo Nordisk A/S were worth $1,325,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. 1620 Investment Advisors Inc. purchased a new position in Novo Nordisk A/S in the second quarter worth $25,000. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Novo Nordisk A/S during the second quarter worth $25,000. Orion Capital Management LLC acquired a new stake in shares of Novo Nordisk A/S during the first quarter worth $26,000. Gilliland Jeter Wealth Management LLC lifted its stake in shares of Novo Nordisk A/S by 200.0% during the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after buying an additional 120 shares during the period. Finally, Halpern Financial Inc. lifted its stake in shares of Novo Nordisk A/S by 113.0% during the second quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock worth $30,000 after buying an additional 113 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

NVO has been the subject of several research reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Finally, BMO Capital Markets lowered their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Buy” and a consensus target price of $144.50.

Novo Nordisk A/S Trading Down 1.5 %

Shares of Novo Nordisk A/S stock opened at $105.35 on Friday. The firm has a 50-day simple moving average of $119.68 and a two-hundred day simple moving average of $129.92. The company has a market cap of $472.76 billion, a P/E ratio of 34.09, a price-to-earnings-growth ratio of 1.29 and a beta of 0.42. Novo Nordisk A/S has a fifty-two week low of $94.73 and a fifty-two week high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.